As clinical designs become more complex and data volumes increase, recruitment and retention of trial participants remains the biggest hurdle for sponsors, opening the door to AI-powered tools.
Some researchers are turning to artificial intelligence and machine learning (ML) to address these challenges and improve operational capabilities. These tools can help you identify the most promising trial sites, increase enrollment by up to 20%, and create real-time enrollment forecasts to enable earlier and more aggressive intervention.
Deploying AI/ML technology can help bring innovative treatments to market faster, reducing development timelines by an average of six months per asset. For example, research shows that cutting clinical development by 12 months can increase the net present value of a sponsor’s portfolio by more than $400 million.
Here are five ways emerging AI and ML tools are being used in clinical research, according to WCG’s 2026 Trends & Insights report.
Optimize site selection with predictive analytics
Predictive analytics is changing the way trial sponsors and CROs approach protocol design and site selection strategies. Based on historical data, comparable protocol performance, and demographic and epidemiological trends, predictive models can identify regional and site profiles most likely to yield optimal participant populations.
This data-driven approach, leveraging predictive algorithms, has the potential to analyze vast amounts of data to meet research needs and reduce dropout rates, making it one of the most impactful AI innovations in the industry, the report highlights.
It also enables teams to make more informed decisions earlier in the trial lifecycle, minimizing costly mid-trial adjustments and protocol changes.
Utilizing proactive clinical trial monitoring with machine learning
The clinical research industry is beginning to shift from reactive problem solving to proactive risk management using machine learning.
Machine learning, powered by models trained on large datasets, allows research teams to identify emerging risks early in the process and address potential bottlenecks before trial schedules are disrupted.
Machine learning also helps sponsors and CROs better allocate resources, proactively address site performance issues, and maintain overall research momentum, ultimately improving the speed and quality of trial execution.
The report suggests that this predictive capability is considered a major advance compared to traditional monitoring methods, which often discover problems after they have already impacted deadlines and data quality.
Promoting protocol development using generative AI
According to the WCG report, large-scale language models and generative AI are expanding the role of augmented intelligence into clinical trial documentation and protocol review processes.
These AI applications can also power AI bots that quickly generate research documents such as informed consent forms and trial protocols, perform preliminary reviews to ensure appropriate regulatory elements are included, and enable research staff to ask specific questions about protocols. This level of automation improves efficiency and consistency by allowing clinical teams to focus on higher-value work rather than spending time on tedious tasks such as document creation.
It can also be useful for more complex tasks such as protocol evaluation and regulatory compliance checks, although human oversight is still required to ensure that expert judgment is part of the review process.
Improving data quality with AI-powered anomaly detection
AI-powered anomaly detection is transforming data quality management in clinical trials by minimizing manual data entry, reducing errors, and monitoring data integrity in real-time. Rather than finding inconsistencies, outliers, and potential data quality issues later during data reviews, integrated platforms and smart data systems with automated compliance checks can help you spot issues as they occur.
This capability is especially valuable as study designs become more sophisticated and datasets grow larger, making manual monitoring difficult and time-consuming.
AI anomaly detection has operational benefits that extend throughout the review stages of regulatory submissions and ongoing research conduct. Continuous monitoring throughout a study creates a feedback loop that facilitates faster decision-making and course correction, while real-time feedback systems speed regulatory submissions by identifying errors before documents are submitted, thereby saving time and improving research integrity.
Transforming patient recruitment and engagement with AI
AI systems are reshaping the way sponsors and sites find, engage, and interact with clinical trial participants during the research process. AI tools can significantly reduce pre-screening time and improve recruitment accuracy by evaluating medical records and determining patient eligibility based on inclusion and exclusion criteria.
AI is also being used to maintain electronic diaries, collect patient-reported outcomes, and support ongoing participant engagement, all of which streamline data collection and reduce the workload of site personnel and trial participants.
However, when implementing AI in participant-facing applications, certain ethical and legal implications must be carefully considered. This is because confidentiality and privacy remain major concerns for participants, especially when personal health data is involved.
As AI technology continues to evolve, strong governance frameworks and human oversight are essential to uphold ethical standards and ensure patient safety.
Alivia Kaylor is a scientist and senior site editor at Pharma Life Sciences.
